Related references
Note: Only part of the references are listed.Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial
Francois Quenet et al.
LANCET ONCOLOGY (2021)
HIPEC Methodology and Regimens: The Need for an Expert Consensus
Aditi Bhatt et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin
Omeed Moaven et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Outcomes of neoadjuvant chemotherapy before CRS-HIPEC for patients with appendiceal cancer
J. C. Chen et al.
JOURNAL OF SURGICAL ONCOLOGY (2020)
Personalized Identification of Optimal HIPEC Perfusion Protocol in Patient-Derived Tumor Organoid Platform
Steven D. Forsythe et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: a systematic review and meta-analysis of comparative studies
Xubing Zhang et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2020)
PRODIGE 7 should be interpreted with caution
Gabriel Liberale et al.
ACTA CHIRURGICA BELGICA (2019)
Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study
Konstantinos I. Votanopoulos et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries
Konstantinos Ioannis Votanopoulos et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
The Role of Neoadjuvant and Adjuvant Systemic Chemotherapy with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Systematic Review
Kathryn Waite et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis
V. Leung et al.
EJSO (2017)
The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study
D. Hompes et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
Outcomes With Cytoreductive Surgery and HIPEC for Peritoneal Metastasis
Shuja Ahmed et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
The American Society of Peritoneal Surface Malignancies Evaluation of HIPEC with Mitomycin C Versus Oxaliplatin in 539 Patients with Colon Cancer Undergoing a Complete Cytoreductive Surgery
Arancha Prada-Villaverde et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Experience with 1,000 Patients
Edward A. Levine et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2014)
Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years
Mariusz Panczyk
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Molecular aspects of cancer cell resistance to chemotherapy
Magali Rebucci et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Prognostic Factors of Peritoneal Metastases from Colorectal Cancer following Cytoreductive Surgery and Perioperative Chemotherapy
Yutaka Yonemura et al.
SCIENTIFIC WORLD JOURNAL (2013)
Systemic Chemotherapy prior to Cytoreductive Surgery and HIPEC for Carcinomatosis from Appendix Cancer: Impact on Perioperative Outcomes and Short-Term Survival
Lana Bijelic et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2012)
Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis
Kurt Van der Speeten et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French Study
Dominique Elias et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Share Paper
